ImmunoCellular Therapeutics Establishes Agreement With Novella Clinical

ImmunoCellular Therapeutics, Ltd. recently announced the establishment of an agreement with Novella Clinical to conduct the Phase III registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small- to mid-sized oncology companies. The ICT-107 Phase III trial will include approximately 120 clinical sites in the US, Europe, and Canada, and will recruit about 400 patients with newly diagnosed glioblastoma. ImmunoCellular anticipates initiating the Phase III trial in the fourth quarter of 2015.

“Establishing this agreement with Novella Clinical moves us one more critical step forward in the implementation of our Phase III ICT-107 registrational trial,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “Novella’s special expertise in oncology clinical trials, combined with their strong international network, experience working with oncology cooperative groups, and reputation for high-quality, efficiency, and cost-effectiveness, make them an excellent partner for our ICT-107 program. We are rapidly building the infrastructure for our phase 3 program and remain on track to initiate the trial later this year.”

“We are proud and very pleased to be selected to support this proprietary oncology immunotherapy platform for glioblastoma. We look forward to working alongside ImmunoCellular to navigate the development and successful execution of this pivotal program to ultimately benefit patients,” added Novella’s President Richard Staub.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based cancer immunotherapy targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting CD133; ICT-140, a dendritic cell immunotherapy targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program, which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer killing T-cells.